Frequencies of individual genotypes were similar to those reported previously in other Caucasian control populations [23–25]. We observed more G-allele carriers in the severe RXDX-106 cost AH patient

group than in other ALD patients. Moreover, among AH patients, the G-allele was more frequent in the severe form of the disease (Table 3a). However, the CCL2 polymorphism −2518G-allele was not associated with patient survival. Indeed, there was no difference in 90-day survival between G-carriers and non-G-carriers patients in the entire population of ALD (88·1% ± 3·5% versus 88·4% ± 3·2%, P = 0·909), nor in a subgroup of patients with alcoholic hepatitis (83·8% ± 5·6% versus 81·6% ± 5·6%, P = 0·792) and severe alcoholic hepatitis (75·9% ± 9·4% versus 64·3% ± 12·8%, P = 0·528). We performed CCR2 190 A/G polymorphism genotyping in this cohort SB525334 solubility dmso of ALD patients and we found no difference between genotypes (Table 3b). In the present study, we show that plasma levels and hepatic expression of CCL2 are increased in a large cohort of biopsy-proven ALD patients, particularly those with severe

AH. Interestingly, this CCL2 over-expression is associated with parameters of disease severity such as hepatic venous pressure gradient and model for end-stage liver disease (MELD) score. We found no relationship between plasma levels or hepatic expression of CCL2 and 90-day survival. Nevertheless, these results should be viewed with caution, as many patients were lost to follow-up. We also measured CCL2 plasma levels in patients with severe AH before Dolutegravir research buy and after 7 days of steroid therapy, and we showed a trend towards decreased CCL2 plasma levels after treatment. However, the reason why the CCL2 plasma level decreased after steroid treatment is not clear, and further studies on a large cohort of AH patients are required. Moreover, we demonstrated that CCL2 liver expression is correlated with neutrophil infiltrates and IL-8 liver expression. CCL2 is a CC chemokine which is chemotactic for monocytes and lymphocytes. Arguments in the literature suggest that, under inflammatory conditions, neutrophils undergo phenotypic changes enabling them

to respond to chemokines that are functionally inactive under resting conditions [26,27]. However, we showed that circulating neutrophils of ALD patients did not express CCR2, suggesting that CCL2 does not directly recruit neutrophils via this receptor. Nevertheless, CCL2 could play a role in neutrophil recruitment via a receptor other than CCR2; indeed, a recent study showed, in an experimental model of ALD, that CCL2-deficient mice were protected against alcoholic liver injury independently of CCR2. Interestingly, KC/IL-8 mRNA liver expression was decreased significantly in alcohol-fed CCL2-deficient mice [16]. In agreement with those results, but in humans, we show a very strong correlation between CCL2 and IL8 mRNA liver expression.